Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Biopharmaceuticals company discusses Q1 results, impact of ACCESS acquisition
May 31st, 2004
Keryx Biopharmaceuticals, Inc., (KERX), a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer, released financial results for the first quarter ended March 31, 2004. As part of a previously announced acquisition of ACCESS Oncology, Inc., the company incurred a noncash, acquired in-process research and development charge in the quarter ended March 31, 2004, of $18.8 million, all of which was included in research and development expenses. This charge arose as a result of purchase accounting treatment for the acquisition, as mandated...
Source: Obesity & Diabetes Week (2004-05-31)
|
